AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME

Mira Peled Kamar; Galit Denkberg; Yoram Reiter; Ilan Beer; Keren Sinik; Yael Teboul (Elbaz); Yael Shperber (Sery); Reut Erel Segal; Ravit Oren; Mira Peled Kamar; Galit Denkberg; Yoram Reiter; IIan Beer; Keren Sinik; Yael Teboul (elbaz); Yael Shperber (sery); Reut Erel Segal; Ravit Oren; Dror Shmuel Alishekevitz; Dror Shmuel Alishekevitz

AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME

Mira Peled Kamar (Inventor), Galit Denkberg (Inventor), Yoram Reiter (Inventor), Ilan Beer (Inventor), Keren Sinik (Inventor), Yael Teboul (Elbaz) (Inventor), Yael Shperber (Sery) (Inventor), Reut Erel Segal (Inventor), Ravit Oren (Inventor), Mira Peled Kamar (Inventor), Galit Denkberg (Inventor), Yoram Reiter (Inventor), IIan Beer (Inventor), Keren Sinik (Inventor), Yael Teboul (elbaz) (Inventor), Yael Shperber (sery) (Inventor), Reut Erel Segal (Inventor), Ravit Oren (Inventor), Dror Shmuel Alishekevitz (Inventor), Dror Shmuel Alishekevitz (Inventor)

Technion - Israel Institute of Technology

Research output: Patent

Abstract

Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.

Original language	American English
Patent number	US2018171024 AA
IPC	G01N 33/ 574 A I
Priority date	8/06/16
State	Published - 21 Jun 2018

Cite this

Peled Kamar, M., Denkberg, G., Reiter, Y., Beer, I., Sinik, K., Teboul (Elbaz), Y., Shperber (Sery), Y., Erel Segal, R., Oren, R., Peled Kamar, M., Denkberg, G., Reiter, Y., Beer, II., Sinik, K., Teboul (elbaz), Y., Shperber (sery), Y., Erel Segal, R., Oren, R., Alishekevitz, D. S., & Alishekevitz, D. S. (2018). AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME. (Patent No. US2018171024 AA).

@misc{456332be95d74bec941af5c723329359,

title = "AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME",

abstract = "Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.",

author = "{Peled Kamar}, Mira and Galit Denkberg and Yoram Reiter and Ilan Beer and Keren Sinik and {Teboul (Elbaz)}, Yael and {Shperber (Sery)}, Yael and {Erel Segal}, Reut and Ravit Oren and {Peled Kamar}, Mira and Galit Denkberg and Yoram Reiter and IIan Beer and Keren Sinik and {Teboul (elbaz)}, Yael and {Shperber (sery)}, Yael and {Erel Segal}, Reut and Ravit Oren and Alishekevitz, {Dror Shmuel} and Alishekevitz, {Dror Shmuel}",

year = "2018",

month = jun,

day = "21",

language = "American English",

type = "Patent",

note = "US2018171024 AA; G01N 33/ 574 A I",

}

Peled Kamar, M, Denkberg, G, Reiter, Y, Beer, I, Sinik, K, Teboul (Elbaz), Y, Shperber (Sery), Y, Erel Segal, R, Oren, R, Peled Kamar, M, Denkberg, G, Reiter, Y, Beer, II, Sinik, K, Teboul (elbaz), Y, Shperber (sery), Y, Erel Segal, R, Oren, R, Alishekevitz, DS & Alishekevitz, DS Jun. 21 2018, AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME, Patent No. US2018171024 AA.

TY - PAT

T1 - AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME

AU - Peled Kamar, Mira

AU - Denkberg, Galit

AU - Reiter, Yoram

AU - Beer, Ilan

AU - Sinik, Keren

AU - Teboul (Elbaz), Yael

AU - Shperber (Sery), Yael

AU - Erel Segal, Reut

AU - Oren, Ravit

AU - Peled Kamar, Mira

AU - Denkberg, Galit

AU - Reiter, Yoram

AU - Beer, IIan

AU - Sinik, Keren

AU - Teboul (elbaz), Yael

AU - Shperber (sery), Yael

AU - Erel Segal, Reut

AU - Oren, Ravit

AU - Alishekevitz, Dror Shmuel

PY - 2018/6/21

Y1 - 2018/6/21

N2 - Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.

AB - Affinity binding entities having TCRL binding domain and methods of their use are provided. More specifically these compositions bind HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP or HLA-A2/TyrD+ cells and as such can be used in diagnostics and therapy.

M3 - Patent

M1 - US2018171024 AA

ER -